EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Efficacy of Fuzheng Quxie Formula Against Postoperative Metastasis of Lung Cancer in Stage IIA-IIIA With Negative Driver Genes: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial

Fan Xu iD, Yun Yang iD, Yinbin Luo iD, Bin Luo iD, Jialiang Yao iD, Yiyang Zhou iD, Minghua Li iD, Jianchun Wu iD, Wenfei Shi iD, Lei Jiang iD, Qian Huang iD, Wentao Fang iD und 3 weitere

JMIR Research Protocols · 2025

DOI: 10.2196/66342 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Fan Xu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai,…. Hauptthemen laut MEDLINE: Lung Neoplasms, Drugs, Chinese Herbal. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastasis is the primary cause of poor prognosis and high mortality in lung cancer. Surgery with postoperative adjuvant chemotherapy is the standard treatment for patients with stage IIA-IIIA lung cancer with negative driver genes. However, recurrence rates remain significant. In China, traditional Chinese medicine shows potential as an adjuvant therapy to reduce treatment toxicity and improve clinical efficacy.

Objective

This study aimed to evaluate its efficacy and safety in preventing postoperative metastasis in driver gene-negative stage IIA-IIIA lung cancer, based on the promising preclinical results of Fuzheng Quxie Formula against lung cancer metastasis. In this trial, we hypothesize that the treatment group will have better efficacy and safety than the control group.

Methods

A multicenter, double-blind, randomized, placebo-controlled parallel group trial will be conducted. Eligible patients will be randomized into a treatment group (daily Fuzheng Quxie Formula granules+regular chemotherapy) and a control group (daily Chinese medicine placebo granules+regular chemotherapy) in a ratio of 1:1. Fuzheng Quxie Formula will be administered orally, twice a day, in the morning and evening, for 6 months. Patients will be followed up after the end of treatment for 18 months. After the end of the program, follow-up will be continued for 5 years or until the patient dies (or progressed). The primary efficacy endpoint is disease-free survival, and the secondary efficacy endpoints are overall survival, minimal residual disease, circulating tumor cells, Chinese medicine symptom score, quality-of-life assessment, immune indicators, tumor markers, peripheral blood systemic immune-inflammation index, and prognostic nutritional index. We will conduct per-protocol analyses on these outcomes. In addition, we will also evaluate the safety of the Fuzheng Quxie Formula.

Results

This study began screening and recruitment in March 2023. Recruitment is ongoing; by the end of 2024, a total of 180 eligible participants will be enrolled. Recruitment will continue until the end of June 2025 or until the target sample is reached. We estimate that the results will be published by March 2026.

Conclusions

This study is a high-quality, large-scale, multicenter, double-blind, randomized controlled trial. This will be the first trial to evaluate the efficacy and safety of Fuzheng Quxie Formula in inhibiting metastasis after surgery in stage IIA-IIIA lung cancer with negative driver genes. Provide a basis for the clinical application of Fuzheng Quxie Formula. Trial Registration ClinicalTrials.gov NCT06381960; https://clinicaltrials.gov/study/NCT06381960 International Registered Report Identifier (IRRID) DERR1-10.2196/66342

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsDrugs, Chinese HerbalHumansDouble-Blind MethodMaleFemaleRandomized Controlled Trials as TopicNeoplasm StagingMulticenter Studies as TopicMiddle AgedMedicine, Chinese TraditionalAdultNeoplasm MetastasisChinaAgedTreatment Outcome

Stichwörter der Autor:innen

Fuzheng Quxie Formulaefficacylung cancer metastasisnegative driver genes expressionsafetytraditional Chinese medicine

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Thoracic Surgery, Shanghai Lung Hospital of Tongji University, Shanghai, China.
  • Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Fan Xu, Yun Yang, Yinbin Luo, Bin Luo, Jialiang Yao, Yiyang Zhou, Minghua Li, Jianchun Wu, Wenfei Shi, Lei Jiang, Qian Huang, Wentao Fang, Zhihong Fang, Yan Li, Jianhui Tian

Zitieren

APA

Xu, F., Yang, Y., Luo, Y., Luo, B., Yao, J., Zhou, Y., Li, M., Wu, J., Shi, W., Jiang, L., Huang, Q., Fang, W., Fang, Z., Li, Y., & Tian, J. (2025). Efficacy of Fuzheng Quxie Formula Against Postoperative Metastasis of Lung Cancer in Stage IIA-IIIA With Negative Driver Genes: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial. JMIR Research Protocols. https://doi.org/10.2196/66342

Vancouver

Xu F, Yang Y, Luo Y, Luo B, Yao J, Zhou Y, et al. Efficacy of Fuzheng Quxie Formula Against Postoperative Metastasis of Lung Cancer in Stage IIA-IIIA With Negative Driver Genes: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial. JMIR Research Protocols. 2025. doi:10.2196/66342

BibTeX
@article{Xu2025,
  author = {Xu, Fan and Yang, Yun and Luo, Yinbin and Luo, Bin and Yao, Jialiang and Zhou, Yiyang and Li, Minghua and Wu, Jianchun and Shi, Wenfei and Jiang, Lei and Huang, Qian and Fang, Wentao and Fang, Zhihong and Li, Yan and Tian, Jianhui},
  title = {Efficacy of Fuzheng Quxie Formula Against Postoperative Metastasis of Lung Cancer in Stage IIA-IIIA With Negative Driver Genes: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/66342}
}
Kostenlos starten →